湖南方盛制药2025年度权益分派实施公告深度解读
公告要点
- 每股现金红利：每股派发人民币0.15元（含税）。
- 股权登记日：2026年5月28日
- 除权（息）日及红利发放日：2026年5月29日
- 本次分红不涉及差异化分红送转。
- 总派息规模：以总股本439,081,360股为基数，共计派发现金红利65,862,204元。
详细内容及亮点解读
1. 分红方案获股东大会批准
本次利润分配方案已于2026年5月15日在2025年年度股东大会上审议通过，彰显公司治理的规范性和对投资者回报的重视。
2. 分红对象及实施方式
所有在2026年5月28日股权登记日下午上海证券交易所收盘后，在中国证券登记结算有限责任公司上海分公司登记在册的股东均有资格获得本次现金红利。无限售条件流通股红利将由中国结算上海分公司通过其资金清算系统自动派发，投资者可在指定证券营业部领取现金红利。对于张庆华、长沙共盛产投咨询有限公司2名特定股东，公司将直接发放红利。
3. 关键日期一览
| 股份类别 | 股权登记日 | 除权（息）日 | 现金红利发放日 |
|---|---|---|---|
| A股 | 2026/5/28 | 2026/5/29 | 2026/5/29 |
4. 税收政策与实际到手红利
- 自然人股东及证券投资基金：持股期限超过1年的，红利暂免个人所得税；持股1个月以内的，实际税负20%；持股1个月以上至1年（含1年）的，实际税负10%。公司派发红利时暂不预扣所得税，待股东转让股票时由券商代扣。
- 有限售条件流通股：解禁后取得的红利参照上述规则，解禁前取得的红利实际税负10%。
- QFII合格境外机构投资者：公司按10%税率统一代扣企业所得税，税后每股实际派发现金红利0.135元。
- 香港联交所投资者：公司按10%税率代扣代缴所得税，税后每股实际派发现金红利0.135元。
- 其他机构投资者和法人股东：公司不代扣企业所得税，每股派发现金红利0.15元。
5. 投资者须知与潜在影响
- 本次分红方案明确、现金红利比例较为稳定，有助于增强市场对公司盈利能力和稳定经营的信心，或将对公司股价形成一定的支撑和正面影响。
- 对于长期持有者，享有免税或低税率红利，利好长期投资者。
- 红利派发日（2026年5月29日）前后，可能出现除权价调整及短线波动，投资者需关注。
- 如有疑问，可联系公司证券部（电话：0731-88997135，传真：0731-88908647，地址：长沙市国家高新技术产业开发区嘉运路299号，邮编：410205）。
6. 结论
湖南方盛制药本次年度分红方案显示出公司现金流充足和盈利能力稳定，分红政策透明，有利于提升投资者信心，是一条具有潜在股价推动力的利好消息。投资者应合理把握分红相关时间节点及税收政策，作出相应投资决策。
免责声明
本文内容仅供参考，不构成任何投资建议。投资者据此操作，风险自负。
English Version
In-Depth Analysis: Hunan Fangsheng Pharmaceutical 2025 Dividend Distribution Announcement
Key Highlights
- Cash Dividend per Share: RMB 0.15 (pre-tax) per share.
- Ex-Dividend & Record Dates: Record date on May 28, 2026; Ex-dividend and payment date on May 29, 2026.
- No differentiated bonus share or transfer.
- Total dividend payout: Based on 439,081,360 shares, total cash dividend is RMB 65,862,204.
Detailed Analysis and Investor Takeaways
1. Dividend Plan Approval
The dividend distribution plan was approved at the 2025 Annual General Meeting of Shareholders held on May 15, 2026, reflecting the company’s sound governance and commitment to shareholder returns.
2. Eligible Recipients and Implementation
All shareholders registered with China Securities Depository and Clearing Corporation Shanghai Branch after the close of trading on May 28, 2026, are eligible for the cash dividend. Dividends for freely tradable shares will be distributed automatically via the clearing system. For specific shareholders, such as Mr. Zhang Qinghua and Changsha Gongsheng Industrial Investment Consulting Co., Ltd., dividends will be paid directly by the company.
3. Key Dates Overview
| Share Class | Record Date | Ex-Dividend Date | Dividend Payment Date |
|---|---|---|---|
| A Shares | 2026/5/28 | 2026/5/29 | 2026/5/29 |
4. Tax Policy and Net Dividend
- Individual shareholders and investment funds: No withholding for holdings over 1 year; 20% tax for holdings up to 1 month; 10% for holdings between 1 month and 1 year. Tax is withheld upon stock transfer, not at time of distribution.
- Restricted shares: Post-unlock dividends follow the same rule; pre-unlock dividends are taxed at 10%.
- QFII investors: Company withholds 10% corporate income tax; net dividend per share: RMB 0.135.
- Hong Kong Stock Connect investors: 10% withholding, net dividend per share: RMB 0.135.
- Other institutional and corporate shareholders: No withholding; full RMB 0.15 per share paid.
5. Investor Considerations & Potential Impact
- This clear and stable dividend plan demonstrates robust cash flow and profitability, likely boosting market confidence and potentially supporting or lifting the share price.
- Long-term shareholders benefit from tax exemptions or lower rates, favoring long-term holding.
- Share price may fluctuate around the ex-dividend date (May 29, 2026) due to price adjustment. Stay alert.
- For inquiries, contact the company’s securities department (Tel: 0731-88997135, Fax: 0731-88908647, Address: 299 Jiayun Road, Changsha High-tech Zone, Postal Code: 410205).
6. Conclusion
Hunan Fangsheng Pharmaceutical’s annual dividend plan signals strong cash reserves and stable profitability. The transparent policy is a positive catalyst for investor confidence and could potentially drive share prices. Investors should be aware of relevant dates and tax implications when planning their investment strategy.
Disclaimer
The content above is for reference only and does not constitute investment advice. Investors assume full responsibility for their own investment decisions.
